Source: Eur Respir J 2010; 36: 608-614
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Domínguez A., Izquierdo C., Salleras L., Ruiz L., Sousa D., Bayas J-M., Nebot M., Varona W., Celorrio J-M., Carratalà  J.. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010; 36: 608-614

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Source: Eur Respir J 2005; 26: 1086-1091 Year: 2005 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Effectiveness of 23-valent pneumococcal polysaccharide vaccine in preventing lower respiratory tract infections complicating chronic respiratory failure Source: Eur Respir J 2006; 28: Suppl. 50, 576s Year: 2006 Should pneumococcal vaccines be used to prevent LRTI? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004 Role of pneumococcal vaccine on the incidence of childhood empyema Source: Breathe 2010; 6: 366-367 Year: 2010 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Efficacy of influenza and pneumococcal vaccinations among patients with COPD Source: Annual Congress 2007 - Treatment of COPD Year: 2007 Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 673s Year: 2005 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015 Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016 Pneumococcal polysaccharide vaccination in COPD patients - some problems with antibody-response Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002